Current practice of hepatitis C treatment in Southern Italy

Dig Liver Dis. 2010 Nov;42(11):822-5. doi: 10.1016/j.dld.2010.03.020.

Abstract

Background: Only a small proportion of subjects referring to hospitals for hepatitis C virus (HCV) positivity receives antiviral therapy.

Aim: To evaluate the rate of antiviral treatment and the causes for no treatment in HCV-RNA positive subjects seen in hospital settings.

Patients and methods: A prospective study enrolling over a 6-month period (February-July 2009) all consecutive anti-HCV positive subjects initially referred (naïve patients) to 12 liver units in Southern Italy for HCV treatment.

Results: Out of 608 subjects evaluated, 74 (12.2%) had no detectable HCV-RNA in the serum and thus were excluded. Of the remaining 534 HCV-RNA positive subjects, 357 (66.9%) were not treated for the following reasons: 49.9% were older than 65 years of age (75% of them >70 years), 14.3% had normal liver enzymes, 13.2% had compensated/decompensated cirrhosis, 10.4% refused treatment, 9.8% had ongoing substance or alcohol abuse. Multivariate analysis showed that females (O.R. 2.27; C.I. 95% 1.05-4.90) and subjects with low educational level (O.R. 4.38; C.I. 95% 1.27-15.11) were more likely to decline therapy.

Conclusions: The majority of patients with HCV infection does not receive antiviral treatment. The effectiveness of the current standard therapy for HCV infection is low despite its good efficacy.

MeSH terms

  • Adult
  • Aged
  • Alanine Transaminase / blood
  • Alcoholism
  • Antiviral Agents / supply & distribution
  • Antiviral Agents / therapeutic use*
  • Educational Status
  • Female
  • Hepacivirus* / drug effects
  • Hepacivirus* / genetics
  • Hepatitis C / drug therapy*
  • Hepatitis C / epidemiology
  • Hepatitis C / immunology
  • Hepatitis C / prevention & control*
  • Hepatitis C Antibodies / blood
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use
  • Italy / epidemiology
  • Male
  • Middle Aged
  • Polyethylene Glycols / therapeutic use
  • Prospective Studies
  • RNA, Viral / blood
  • Recombinant Proteins
  • Ribavirin / therapeutic use
  • Sex Factors
  • Treatment Outcome
  • Treatment Refusal

Substances

  • Antiviral Agents
  • Hepatitis C Antibodies
  • Interferon alpha-2
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • Alanine Transaminase
  • peginterferon alfa-2b